LevitasBio, Inc. today unveiled the LeviCell™ EOS System, their next generation solution for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells.
LevitasBio has announced the expansion of its product portfolio with the release of two new product lines that will enable researchers and laboratory personnel to better process and characterize human, animal and plant samples.
Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.
Explore how blood-based biomarkers perform across Alzheimer’s disease stages, including AIBL Study findings comparing p-Tau217 and other markers against amyloid-beta and tau PET reference standards.
Explore how super-resolution microscopy enables particle-level characterization of lipid nanoparticle composition, cargo loading, heterogeneity, and stability, providing complementary insights for formulation development and optimization.
The placements follow the commercial launch of Pyxa at the Advances in Genome Biology and Technology (AGBT) meeting in February 2026 and mark the company's transition from Early Access into global commercial availability.
The CellRaft AIR streamlines antibody discovery with imaging, functional screening, and gentle isolation of viable single B cells and hybridomas, helping verify monoclonality and identify high producing clones faster.
Load plasma directly into prefilled cartridges, no pretreatment, no ethanol. Under 30 minutes of instrument run time, up to 48 samples in parallel, with a high-throughput format also available.
Two Paige tools, powered by the Virchow pathology foundation model, are now available within a single image management workspace for oncology research.
